Assignee
ORIONIS BIOSCIENCES INC
US·17 granted patents·21 pending applications·16 citations·filing 2018–2025
Top patents by PatentIndex Score
38 records- 0193US10906985B2Targeted engineered interferon and uses thereofORIONIS BIOSCIENCES INC·Filed 2018·Granted Feb 2, 2021·8 cites·16 claims
- 0290US11440943B2Therapeutic interferon alpha 1 proteinsORIONIS BIOSCIENCES INC·Filed 2020·Granted Sep 13, 2022·2 cites·11 claims
- 0387US12473338B2Targeted engineered interferon and uses thereofORIONIS BIOSCIENCES INC·Filed 2020·Granted Nov 18, 2025·1 cites·6 claims
- 0481US2025066486A1Clec9a binding agents and use thereofORIONIS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 0580US12091463B2Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)ORIONIS BIOSCIENCES INC·Filed 2018·Granted Sep 17, 2024·1 cites·8 claims
- 0680US2024360224A1Clec9a binding agents and use thereofORIONIS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 0779US12576127B2Fibroblast binding agents and use thereofORIONIS BIOSCIENCES INC·Filed 2024·Granted Mar 17, 2026·0 cites·8 claims
- 0879US12084497B2SIRP1α targeted chimeric proteins and uses thereofORIONIS BIOSCIENCES INC·Filed 2019·Granted Sep 10, 2024·1 cites·14 claims
- 0979US11498966B2PD-1 and PD-L1 binding agentsORIONIS BIOSCIENCES INC·Filed 2018·Granted Nov 15, 2022·1 cites·8 claims
- 1078US11566072B2CD8 binding agentsORIONIS BIOSCIENCES INC·Filed 2018·Granted Jan 31, 2023·1 cites·22 claims
- 1178US2025361305A1Pd-1 and pd-l1 binding agentsORIONIS BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 1276US12351633B2PD-1 and PD-L1 binding agentsORIONIS BIOSCIENCES INC·Filed 2022·Granted Jul 8, 2025·0 cites·16 claims
- 1376US11896643B2Fibroblast binding agents and use thereofORIONIS BIOSCIENCES INC·Filed 2019·Granted Feb 13, 2024·1 cites·11 claims
- 1475US2024368277A1SIRP1a TARGETED CHIMERIC PROTEINS AND USES THEREOFORIONIS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1572US12448447B2CD8 binding agentsORIONIS BIOSCIENCES INC·Filed 2022·Granted Oct 21, 2025·0 cites·14 claims
- 1670US12583898B2Therapeutic interferon alpha 1 proteinsORIONIS BIOSCIENCES INC·Filed 2022·Granted Mar 24, 2026·0 cites·9 claims
- 1768US2025353890A1Clec9a-based chimeric protein complexesORIONIS BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 1865US12351614B2CLEC9A-based chimeric protein complexesORIONIS BIOSCIENCES INC·Filed 2020·Granted Jul 8, 2025·0 cites·5 claims
- 1962US2024400633A1Split human ifn-gamma and tnf-alpha constructs and uses thereofORIONIS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2061US2024358826A1Interleukin-1 alpha chimeric proteinORIONIS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2161US2025171531A1Il-2 trap moleculesORIONIS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2258US2024199714A1Il-2 based constructsORIONIS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2356US2023293652A1Immunostimulatory adjuvantsORIONIS BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2453US12546776B2Modulation of protein degradationORIONIS BIOSCIENCES INC·Filed 2020·Granted Feb 10, 2026·0 cites·20 claims
- 2553US2023002493A1Pd-l1 targeted chimeric proteins and uses thereofORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 2653US2022378925A1Conjugated chimeric proteinsORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 2752US12583941B2Fibroblast activation protein binding agents and use thereofORIONIS BIOSCIENCES INC·Filed 2020·Granted Mar 24, 2026·0 cites·17 claims
- 2852US12410225B2Modulation of dendritic cell lineagesORIONIS BIOSCIENCES INC·Filed 2019·Granted Sep 9, 2025·0 cites·17 claims
- 2951US2023116707A1Detection of novel degradation-related interactionsORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3051US2022177550A1Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3)ORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3151US2022185857A1Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteinsORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3250US12544426B2Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexesORIONIS BIOSCIENCES INC·Filed 2020·Granted Feb 10, 2026·0 cites·11 claims
- 3349US2023026360A1Detection of molecular interactionsORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3447US2021024631A1Bi-functional proteins and construction thereofORIONIS BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3547US2020354424A1Xcr1 binding agents and uses thereofORIONIS BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3642US2023111853A1Compounds modulating protein recruitment and/or degradationORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3742US2022026439A1Particle based small molecule-protein complex trapORIONIS BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3842US2023099031A1Bifunctional agents for protein recruitment and/or degradationORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ORIONIS BIOSCIENCES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →